Cross-Sector entity
All 2 tracked stories fall under one category: pharma. AbbVie is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Across a 152-day span, the pace is roughly 0.1 stories per week. Rinvoq appears in 2 tracked Cross-Sector stories published from February 27, 2026 through July 28, 2026.
2 verified stories tracked
Last mentioned: Jul 28, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 2 tracked stories fall under one category: pharma. AbbVie is the most frequent co-covered peer, appearing in 2 of the 2 tracked stories. Across a 152-day span, the pace is roughly 0.1 stories per week. Rinvoq appears in 2 tracked Cross-Sector stories published from February 27, 2026 through July 28, 2026. The tracked stories average 2 original sources each.
Computed from the 2 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Rinvoq. Shared-story counts are live from our verified record — not editorial picks.
AbbVie's second-quarter results, expected to show $3.61 EPS, hinge on the continued clinical and commercial success of Rinvoq and Skyrizi. The Apogee deal underscores a deepening immunology pipeline as Humira fades into the rearview.
Source: The Motley Fool · Thomas Niel (us)
RBC Capital has launched coverage of pharmaceutical giant AbbVie with an Outperform rating, signaling confidence in the company's growth trajectory. The initiation suggests that market concerns regarding biosimilar competition for Humira are overstated as newer immunology assets gain significant market share.
Source: finance.yahoo.com · insidermonkey.com
